Member of Lyonbiopole
TOLLYS develops new ligands of Toll Like Receptor 3 (TLR3)as specific immunotherapies with immunological induced memory in the field of cancer (personnalized vaccines). TOLLYS is actually seeking for funds to perform preclincal studies and go through phase I clinical study.
Strategic application domain: Human Medicine
Application market: Oncology
Type of activity: Therapeutics, Pharma or Biotech
Technologies: Molecular Biology & Nucleic acid, Vaccine
Created on july 2nd, 2015 - 13 employees
Address
60 F avenue Rockefeller 69008 LYON 08
Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.
